Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease
Phase of Trial: Phase IV
Latest Information Update: 02 Jan 2017
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PCV13inSIBDCS
- 29 Dec 2016 Status changed from recruiting to completed.
- 24 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 21 Aug 2013 New trial record